April 2022 FDA Recall Gavilyte - C by Lupin Pharmaceuticals Inc.
D-0875-2022 - Failed Stability Specification
This Class II drug recall was voluntarily initiated by Lupin Pharmaceuticals Inc. on April 27, 2022 for the product Gavilyte - C. The FDA reported the reason for recall as failed stability specification. The product was distributed Nationwide and the recall is currently terminated.
Recall Number: D-0875-2022
Failed Stability Specification
04-27-2022
05-25-2022
26,910 bottles
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Lupin Pharmaceuticals Inc.
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Product was distributed nationwide, including Puerto Rico.
04-13-2023
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
GaviLyte -C (Polyethylene Glycol 3350, 240 g) and electrolytes for Oral Solution, USP with flavor pack NDC# 43386-060-19
Batch or Lot Expiration Information
Lot# S001132, exp. date July 2022 NDC # 43386-060-19